Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Immunogenicity Testing Guidance Is High-Wire Act For Brand Industry

Executive Summary

The biotech industry faces a tightrope challenge in commenting on FDA's draft guidance on assay development for immunogenicity testing of therapeutic proteins. Companies want clarity from the agency, as well as limits to the scope of the guidelines. But firms also want to make sure that however the lines are drawn, follow-on biologics have strict testing requirements

You may also be interested in...



Follow-On Biologics One Possible Fruit Of FDA-Northeastern Collaboration

A research collaboration agreement between FDA and Northeastern University could help agency officials understand the mechanisms of action of follow-on biologics, thus easing the way for these products once Congress establishes an approval pathway

Follow-On Biologics One Possible Fruit Of FDA-Northeastern Collaboration

A research collaboration agreement between FDA and Northeastern University could help agency officials understand the mechanisms of action of follow-on biologics, thus easing the way for these products once Congress establishes an approval pathway

FDA Biosimilars Program Gets Seed Money In Administration's FY '11 Budget

FDA plans to spend $5.7 million in fiscal 2011 to develop drug review standards and make other preparations for an approval pathway for follow-on biologics

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel